Literature DB >> 29956471

An intra-individual surgical wound comparison shows that octenidine-based hydrogel wound dressing ameliorates scar appearance following abdominoplasty.

Johannes Matiasek1,2, Philip Kienzl3, Lukas W Unger4, Christoph Grill2, Rupert Koller2, Bela R Turk1,5.   

Abstract

Hypertrophic scar formation because of surgical procedures is associated with higher levels of pain, a lower quality of life, and poor cosmetic outcome and requires more resources in follow-up management. An octenidine-based hydrogel has been shown to modulate immunological function in an in vitro wound model, suggesting an improved scar formation. In this prospective, randomised, observer-blinded, and intra-patient-controlled study, 45 patients who underwent abdominoplasty or mastectomy with transverse rectus abdominis muscle (TRAM) flap reconstruction were given both a standard postoperative wound dressing on one wound side and an octenidine-based hydrogel with transparent film dressing, covered with standard postoperative dressing on the other side. Four instances of hypertrophia were reported in the gel side versus 12 in the standard dressing side. Visual Analogue Scale (VAS) pain scores taken during postoperative dressing changes showed reduced scores on the gel side at all time points. Vancouver Scar Scale (VSS) scores showed improvement in the gel side at 3, 6, and 12 months postoperatively. Skin distensibility measured using a cutometer showed significantly improved measures in gel-treated wounds, similar to measures of healthy skin. Trans-epidermal water loss (TEWL), measured using a tewameter, showed improved values on the gel side soon after surgery, with both the control and the gel side normalising after approximately 6 months. The octenidine-based wound dressing demonstrates improved wound healing associated with a lower incidence of hypertrophic scar formation.
© 2018 Medicalhelplines.com Inc and John Wiley & Sons Ltd.

Entities:  

Keywords:  octenidine; scar; surgical dressing; wound healing

Mesh:

Substances:

Year:  2018        PMID: 29956471      PMCID: PMC7950032          DOI: 10.1111/iwj.12944

Source DB:  PubMed          Journal:  Int Wound J        ISSN: 1742-4801            Impact factor:   3.315


  27 in total

Review 1.  On the nature of hypertrophic scars and keloids: a review.

Authors:  F B Niessen; P H Spauwen; J Schalkwijk; M Kon
Journal:  Plast Reconstr Surg       Date:  1999-10       Impact factor: 4.730

Review 2.  Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies.

Authors:  Gerd G Gauglitz; Hans C Korting; Tatiana Pavicic; Thomas Ruzicka; Marc G Jeschke
Journal:  Mol Med       Date:  2010-10-05       Impact factor: 6.354

Review 3.  Keloids--clinical diagnosis, pathogenesis, and treatment options.

Authors:  Alexander G Marneros; Thomas Krieg
Journal:  J Dtsch Dermatol Ges       Date:  2004-11       Impact factor: 5.584

Review 4.  Scar treatments: preclinical and clinical studies.

Authors:  Richard G Reish; Elof Eriksson
Journal:  J Am Coll Surg       Date:  2008-01-28       Impact factor: 6.113

5.  The patient-reported impact of scars measure: development and validation.

Authors:  Benjamin C Brown; Stephen P McKenna; Mattea Solomon; Jeanette Wilburn; Duncan A McGrouther; Ardeshir Bayat
Journal:  Plast Reconstr Surg       Date:  2010-05       Impact factor: 4.730

6.  Influence of different cosmetic formulations on the human skin barrier.

Authors:  K Heinrich; U Heinrich; H Tronnier
Journal:  Skin Pharmacol Physiol       Date:  2014-01-11       Impact factor: 3.479

Review 7.  Management of scars: updated practical guidelines and use of silicones.

Authors:  Sylvie Meaume; Anne Le Pillouer-Prost; Bertrand Richert; Diane Roseeuw; Javid Vadoud
Journal:  Eur J Dermatol       Date:  2014 Jul-Aug       Impact factor: 3.328

8.  [Keloid scars on black skin: myth or reality].

Authors:  K C Allah; S Yéo; H Kossoko; V Assi Djè Bi Djè; M Richard Kadio
Journal:  Ann Chir Plast Esthet       Date:  2012-04-27       Impact factor: 0.660

9.  Quantitative measurement of hypertrophic scar: intrarater reliability, sensitivity, and specificity.

Authors:  Bernadette Nedelec; José A Correa; Grazyna Rachelska; Alexis Armour; Léo LaSalle
Journal:  J Burn Care Res       Date:  2008 May-Jun       Impact factor: 1.845

10.  The hidden cost of skin scars: quality of life after skin scarring.

Authors:  B C Brown; S P McKenna; K Siddhi; D A McGrouther; A Bayat
Journal:  J Plast Reconstr Aesthet Surg       Date:  2008-07-09       Impact factor: 2.740

View more
  5 in total

1.  An intra-individual surgical wound comparison shows that octenidine-based hydrogel wound dressing ameliorates scar appearance following abdominoplasty.

Authors:  Johannes Matiasek; Philip Kienzl; Lukas W Unger; Christoph Grill; Rupert Koller; Bela R Turk
Journal:  Int Wound J       Date:  2018-06-29       Impact factor: 3.315

2.  Comparative assessment of commercially available wound gels in ex vivo human skin reveals major differences in immune response-modulatory effects.

Authors:  S Seiser; D Cerbu; A Gallhofer; J Matiasek; A Elbe-Bürger
Journal:  Sci Rep       Date:  2022-10-19       Impact factor: 4.996

3.  The Effects of the Transforming Growth Factor-β1 (TGF-β1) Signaling Pathway on Cell Proliferation and Cell Migration are Mediated by Ubiquitin Specific Protease 4 (USP4) in Hypertrophic Scar Tissue and Primary Fibroblast Cultures.

Authors:  Yong Huang; Yuting Wang; Xueming Wang; Lixin Lin; Peng Wang; Junjun Sun; Lei Jiang
Journal:  Med Sci Monit       Date:  2020-04-20

4.  Octenidine-based hydrogel shows anti-inflammatory and protease-inhibitory capacities in wounded human skin.

Authors:  Saskia Seiser; Lukas Janker; Nina Zila; Michael Mildner; Ana Rakita; Johannes Matiasek; Andrea Bileck; Christopher Gerner; Verena Paulitschke; Adelheid Elbe-Bürger
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

5.  Caesarean Scar Endometriosis May Require Abdominoplasty.

Authors:  Barczyński Bartłomiej; Sobstyl Małgorzata; Frąszczak Karolina; Sobstyl Anna
Journal:  Clin Med Insights Case Rep       Date:  2021-06-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.